|
PEG-Interferon alfa-2b in Treating Patients With Metastatic Kidney Cancer Clinical Trials Resources presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, visits or professional assistance with a real medical. We aren't doctors. Always consult your mD about PEG-Interferon alfa-2b in Treating Patients With Metastatic Kidney Cancer conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. PEG-Interferon alfa-2b in Treating Patients With Metastatic Kidney Cancer Clinical research trials and PEG-Interferon alfa-2b in Treating Patients With Metastatic Kidney Cancer health trials occur in a lot of of places throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new does drugs. The role of the studies / projects is to resolve certain human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector corporations to detect remedies for all varieties of circumstances, such as PEG-Interferon alfa-2b in Treating Patients With Metastatic Kidney Cancer. PEG-Interferon alfa-2b in Treating Patients With Metastatic Kidney Cancer Clinical Trials and other clinical trials allow volunteers to obtain health treatment choices before they are available to the general public. Most times the human subjects recieve professional assistance for free of charge, and every now and again they are paid for their time. Sometimes there is a cost for a PEG-Interferon alfa-2b in Treating Patients With Metastatic Kidney Cancer clinical trial. Human subjects frequently get the finest healthcare available for their PEG-Interferon alfa-2b in Treating Patients With Metastatic Kidney Cancer condition. Risks are a reality, however, and may include extra or frequent physician visits, medical dangers (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > PEG-Interferon alfa-2b in Treating Patients With Metastatic Kidney Cancer  PEG-Interferon alfa-2b in Treating Patients With Metastatic Kidney Cancer
PEG-Interferon alfa-2b in Treating Patients With Metastatic Kidney Cancer
For Condition: stage 4 renal cell cancer
Status: Recruiting
Sponsor(s): Memorial Sloan-Kettering Cancer Center , National Cancer Institute (NCI)
Synopsis: RATIONALE: PEG-interferon alfa-2b may stop the growth of kidney cancer by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of PEG-interferon alfa-2b in treating patients who have metastatic kidney cancer.
Details: OBJECTIVES: - Determine the efficacy of PEG-interferon alfa-2b in patients with metastatic renal cell carcinoma. - Determine the time to disease progression in patients treated with this drug. - Determine the safety of this drug in these patients. - Determine the quality of life of patients treated with this drug. - Determine the effect of this drug on biological surrogates of antitumor activity (basic fibroblast growth factor, vascular endothelial growth factor, and interleukin-6 serum levels) in these patients. OUTLINE: Patients receive PEG-interferon alfa-2b subcutaneously once weekly. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline, at 2 weeks and at 2, 4, 8, and 12 months after initiation of study therapy, and then at completion of study therapy. PROJECTED ACCRUAL: A total of 45 patients will be accrued for this study within 15 months.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed renal cell carcinoma - Metastatic disease - No prior therapy for advanced disease - Tumor sample available for molecular analysis with prior registration on MSKCC IRB # 89-076 - Bidimensionally measurable disease - No brain metastases unless completely resected and without evidence of recurrence for at least six months PATIENT CHARACTERISTICS: Age - 18 and over Performance status - Karnofsky 70-100% Life expectancy - Not specified Hematopoietic - WBC at least 3,000/mm3 - Platelet count at least 100,000/mm3 Hepatic - Bilirubin no greater than 1.5 mg/dL - SGOT no greater than 2.5 times upper limit of normal (unless due to hepatic metastases) - Hepatitis B surface antigen negative - Hepatitis C negative Renal - Creatinine no greater than 2 mg/dL Cardiovascular - No severe cardiac disease - No New York Heart Association class III or IV cardiac disease - No myocardial infarction within the past 12 months - No ventricular tachyarrhythmias requiring ongoing treatment - No unstable angina Pulmonary - No severe asthma requiring chronic systemic steroids Other - HIV negative - Negative pregnancy test - Fertile patients must use effective contraception - No malignancy within the past 2 years except basal cell or squamous cell skin cancer, superficial bladder cancer, or localized prostate cancer - Patients who have undergone potentially curative therapy and have been deemed to be at low risk for recurrence are eligible - No medically significant psychiatric disease (e.g., endogenous depression, psychosis, or bipolar disease) requiring hospitalization - No prior or active autoimmune disease - Medically controlled diabetes or thyroid dysfunction allowed - No clinically significant acute viral or bacterial infection that requires specific therapy PRIOR CONCURRENT THERAPY: Biologic therapy - No prior interleukin-2 - No prior interferon alfa - No concurrent cytokines or biological response modifiers except epoetin alfa in the case of hematologic compromise - No concurrent tumor vaccines - No concurrent monoclonal antibodies - No concurrent bone marrow/stem cell transplantation Chemotherapy - No concurrent cytotoxic agents Endocrine therapy - No concurrent high-dose systemic steroids - Concurrent low-dose corticosteroids (e.g., asthma inhalers, topical creams, or intra-articular injections) allowed - No concurrent hormonal therapy (including megestrol) - Concurrent hormone replacement therapy or oral contraceptives allowed Radiotherapy - At least 4 weeks since prior radiotherapy - No concurrent radiotherapy Surgery - See Disease Characteristics - At least 4 weeks since prior major surgery - Concurrent nephrectomy allowed Other - At least 14 days since prior anti-infectious therapy - No other concurrent investigational drugs
Total Enrollment:
Location and Contact Information:
Overall Study Official:
RobertMotzer, Study Chair, Memorial Sloan-Kettering Cancer Center
Memorial Sloan-Kettering Cancer Center *Recruiting*
New York City, New York, 10021
United States
Recruiting Beverly Drucker 646-422-4466
Additional Information:
Study ID Numbers: CDR0000256464; NCI-G-02-2102,MSKCC-01143
Study Start Date:
Record last reviewed: October 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00045279
Other Stage 4 Renal Cell Cancer Studies:
1. Bryostatin 1 in Treating Patients With Metastatic Kidney Cancer
2. Antineoplaston Therapy in Treating Patients With Stage IV Kidney Cancer
3. AG-013736 as Second-Line Therapy in Treating Patients With Metastatic Renal Cell (Kidney) Cancer
4. Interleukin-2 and Bryostatin 1 in Treating Patients With Advanced Kidney Cancer
5. Denileukin Diftitox in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer
Related Studies:
Other stage 4 renal cell cancer Clinical Trials
Other New York Clinical Trials
Other New York City Clinical Trials
PEG-Interferon alfa-2b in Treating Patients With Metastatic Kidney Cancer
|
|
|
|
|
|
|
|
